Treating Hematological Malignancies With OR ‐2100, an Orally Bioavailable Prodrug of Decitabine
Cancer Science · 2025
DOI: 10.1111/cas.16452 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Science, 2025. Verfasst von Tatsuro Watanabe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Prodrugs, Azacitidine, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shinnihon Foundation of Advanced Medical Treatment Research, OHARA Pharmaceutical Co Ltd, Nippon Shinyaku.
Abstract (Originalsprache)
DNA methylation is an enzyme‐driven epigenetic modification that must be precisely regulated to maintain cellular homeostasis. Aberrant methylation status, especially hypermethylation of the promoter sites of tumor‐suppressor genes, is observed in human malignancies and is a proven target for cancer therapy. The first‐generation DNA demethylating agents, azacitidine and decitabine, are widely used for treating several hematological malignancies. In addition, orally bioavailable prodrugs of azacitidine and decitabine have recently been approved by the FDA. We have developed a silylated derivative of decitabine, OR‐2100, which is resistant to degradation by cytidine deaminase and orally bioavailable. It has efficacy against several human hematological malignancies in xenograft mouse models with less hematotoxicity than decitabine. Since DNA demethylating agents are combined with molecularly targeted drugs in clinical use and trials, we think that the less hematotoxic profile of OR‐2100 makes it suitable for use as a combination therapy. In this article, we review the therapeutic approach in hematological malignancies with the DNA demethylating agent OR‐2100.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan.
- Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
ORCID-Profile: Tatsuro Watanabe, Shinya Kimura
Förderung
- Shinnihon Foundation of Advanced Medical Treatment Research
- OHARA Pharmaceutical Co Ltd
- Nippon Shinyaku
- Yasuda Memorial Medical Foundation
- JSPS KAKENHI
- Ohara Pharmaceuticals
Zitieren
APA
Watanabe, T., Kidoguchi, K., & Kimura, S. (2025). Treating Hematological Malignancies With OR ‐2100, an Orally Bioavailable Prodrug of Decitabine. Cancer Science. https://doi.org/10.1111/cas.16452
Vancouver
Watanabe T, Kidoguchi K, Kimura S. Treating Hematological Malignancies With OR ‐2100, an Orally Bioavailable Prodrug of Decitabine. Cancer Science. 2025. doi:10.1111/cas.16452
BibTeX
@article{Watanabe2025,
author = {Watanabe, Tatsuro and Kidoguchi, Keisuke and Kimura, Shinya},
title = {Treating Hematological Malignancies With OR ‐2100, an Orally Bioavailable Prodrug of Decitabine},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.16452}
}
EUVIMED